Context Therapeutics (NASDAQ:CNTX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Context Therapeutics (NASDAQ:CNTX) from a sell rating to a hold rating in a research report released on Saturday morning.

Several other brokerages have also weighed in on CNTX. Guggenheim reaffirmed a “buy” rating and issued a $5.00 target price on shares of Context Therapeutics in a research report on Tuesday, March 24th. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a research report on Tuesday, March 24th. Lifesci Capital raised Context Therapeutics to a “strong-buy” rating in a research report on Monday, February 23rd. Piper Sandler increased their target price on Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.60.

Context Therapeutics Stock Up 2.1%

CNTX stock opened at $2.38 on Friday. Context Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.62. The stock’s fifty day simple moving average is $2.62 and its 200-day simple moving average is $1.90. The stock has a market capitalization of $218.67 million, a price-to-earnings ratio of -5.67 and a beta of 1.57.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.03. As a group, analysts anticipate that Context Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Trading of Context Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Sanctuary Advisors LLC acquired a new stake in Context Therapeutics in the 1st quarter valued at $51,000. Virtu Financial LLC acquired a new stake in Context Therapeutics in the 4th quarter valued at $43,000. Quadrature Capital Ltd acquired a new stake in Context Therapeutics in the 4th quarter valued at $68,000. Clear Harbor Asset Management LLC increased its holdings in Context Therapeutics by 60.5% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after purchasing an additional 35,000 shares in the last quarter. Finally, XTX Topco Ltd increased its holdings in Context Therapeutics by 858.8% in the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after purchasing an additional 91,008 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.

More Context Therapeutics News

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Lifesci Capital raised its Q2 2026 EPS estimate for Context Therapeutics to $(0.09) from $(0.13), suggesting a smaller near-term loss and improving operating trends.
• Positive Sentiment: Lifesci Capital increased its Q3 2026 EPS estimate to $(0.10) from $(0.16), while maintaining a Strong-Buy rating on CNTX.
• Positive Sentiment: Lifesci Capital also lifted its Q4 2026 EPS estimate to $(0.13) from $(0.19) and its FY2026 estimate to $(0.41) from $(0.62), indicating a more favorable full-year outlook.
• Positive Sentiment: HC Wainwright similarly raised its Q2, Q3, and Q4 2026 EPS forecasts, plus its FY2026 and FY2027 estimates, reinforcing the view that losses may be narrower than previously expected.
• Positive Sentiment: HC Wainwright also boosted longer-term FY2028 and FY2029 EPS estimates, which can support investor confidence in Context Therapeutics’ longer-run earnings trajectory.
• Neutral Sentiment: Despite the revisions, analyst forecasts still call for losses over the next several quarters, and the company’s latest reported quarterly EPS of $(0.09) only modestly beat expectations.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.